To provide a low-molecular lysophosphatidic acid (LPA) receptor agonist and a prophylactic or therapeutic agent for various kinds of diseases caused by an LPA receptor, containing the agonist as an active ingredient.
The LPA receptor agonist is composed of an indoloquinolizine derivative represented by general formula (I) (wherein X is methylene or ethylene; R1 is a hydrogen atom or a lower alkyl group or benzyl group which may be substituted; R2 and R3 are each independently a hydrogen atom or a lower alkyl). The prophylactic or therapeutic agent comprises the agonist as an active ingredient. 12-Benzyl-12b-methyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine which is a new compound represented by general formula (I) (wherein R1 is a benzyl group; R2 is a methyl group; R3 is a hydrogen atom) exhibits, especially, strong LPA receptor agonist action. The prophylactic or therapeutic agent, especially, has effects for treating urinary system diseases, central nervous system diseases or peripheral nervous system diseases caused by the LPA receptor.
KONDO YUTAKA
SHISHIKURA JUNICHI
TAKAHASHI MASAYASU
SAKAMOTO KAZUSHI
SOGA TAKATOSHI
ORITA MASAYA
Emiko Yano
鈴木 ▲頼▼子
Hamai Kosuke
Next Patent: AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION